サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1122736

世界の経口粘膜薬物市場：考察と予測 (2028年まで)

Global Oral Transmucosal Drugs Market Insights, Forecast to 2028
出版日: | 発行: QYResearch | ページ情報: 英文 132 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
世界の経口粘膜薬物市場：考察と予測 (2028年まで)
出版日: 2022年09月07日
発行: QYResearch
ページ情報: 英文 132 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、経口粘膜薬物 (Oral Transmucosal Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • 経口粘膜薬物の製品概要
  • 市場：タイプ別
    • 世界の経口粘膜薬物の市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
    • Tablets
    • Films
    • Liquid Spray
    • Gels
    • Others
  • 市場：アプリケーション別
    • 世界の経口粘膜薬物の市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
    • Cardiovascular Disorders
    • Acute Pain Managements
    • Diabetes
    • Others
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界の経口粘膜薬物の販売 推定および予測 2017-2028
  • 世界の経口粘膜薬物の収益 推定および予測 2017-2028
  • 世界の経口粘膜薬物の収益：地域別: 2017 VS 2021 VS 2028
  • 世界の経口粘膜薬物の販売：地域別
    • 世界の経口粘膜薬物の販売：地域別 (2017-2022)
    • 世界の販売 経口粘膜薬物 ：地域別 (2023-2028)
  • 世界の経口粘膜薬物の収益：地域別
    • 世界の経口粘膜薬物の収益：地域別 (2017-2022)
    • 世界の経口粘膜薬物の収益：地域別 (2023-2028)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第3章 競合：メーカー別

  • 世界の経口粘膜薬物の販売：メーカー別
    • 世界の経口粘膜薬物の上位メーカー：販売別 (2017-2022)
    • 世界の経口粘膜薬物の販売市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5メーカー： 経口粘膜薬物2021
  • 世界の経口粘膜薬物の収益：メーカー別
    • 世界の経口粘膜薬物の収益：メーカー別 (2017-2022)
    • 世界の経口粘膜薬物の収益市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5企業： 経口粘膜薬物の収益 2021
  • 世界の経口粘膜薬物の販売価格：メーカー別 (2017-2022)
  • 競合情勢の分析
    • メーカーの市場集中度 (CR5 and HHI)
    • 世界の経口粘膜薬物の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
    • 世界の経口粘膜薬物のメーカーの地理的分布
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界の経口粘膜薬物の販売：タイプ別
    • 世界の経口粘膜薬物の販売実績：タイプ別 (2017-2022)
    • 世界の経口粘膜薬物の販売予測：タイプ別 (2023-2028)
    • 世界の経口粘膜薬物の販売市場シェア：タイプ別 (2017-2028)
  • 世界の経口粘膜薬物の収益：タイプ別
    • 世界の経口粘膜薬物の収益実績：タイプ別 (2017-2022)
    • 世界の経口粘膜薬物の収益予測：タイプ別 (2023-2028)
    • 世界の経口粘膜薬物の収益市場シェア：タイプ別 (2017-2028)
  • 世界の経口粘膜薬物の価格：タイプ別
    • 世界の経口粘膜薬物の価格：タイプ別 (2017-2022)
    • 世界の経口粘膜薬物の価格予測：タイプ別 (2023-2028)

第5章 市場規模：アプリケーション別

  • 世界の経口粘膜薬物の販売：アプリケーション別
    • 世界の経口粘膜薬物の販売実績：アプリケーション別 (2017-2022)
    • 世界の経口粘膜薬物の販売予測：アプリケーション別 (2023-2028)
    • 世界の経口粘膜薬物の販売市場シェア：アプリケーション別 (2017-2028)
  • 世界の経口粘膜薬物の収益：アプリケーション別
    • 世界の経口粘膜薬物の収益実績：アプリケーション別 (2017-2022)
    • 世界の経口粘膜薬物の収益予測：アプリケーション別 (2023-2028)
    • 世界の経口粘膜薬物の収益市場シェア：アプリケーション別 (2017-2028)
  • 世界の経口粘膜薬物の価格：アプリケーション別
    • 世界の経口粘膜薬物の価格：アプリケーション別 (2017-2022)
    • 世界の経口粘膜薬物の価格予測：アプリケーション別 (2023-2028)

第6章 北米

  • 北米の経口粘膜薬物 市場規模：タイプ別
    • 北米の経口粘膜薬物の販売：タイプ別 (2017-2028)
    • 北米の経口粘膜薬物の収益：タイプ別 (2017-2028)
  • 北米の経口粘膜薬物 市場規模：アプリケーション別
    • 北米の経口粘膜薬物の販売：アプリケーション別 (2017-2028)
    • 北米の経口粘膜薬物の収益：アプリケーション別 (2017-2028)
  • 北米の経口粘膜薬物 市場規模：国別
    • 北米の経口粘膜薬物の販売：国別 (2017-2028)
    • 北米の経口粘膜薬物の収益：国別 (2017-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州の経口粘膜薬物 市場規模：タイプ別
    • 欧州の経口粘膜薬物の販売：タイプ別 (2017-2028)
    • 欧州の経口粘膜薬物の収益：タイプ別 (2017-2028)
  • 欧州の経口粘膜薬物 市場規模：アプリケーション別
    • 欧州の経口粘膜薬物の販売：アプリケーション別 (2017-2028)
    • 欧州の経口粘膜薬物の収益：アプリケーション別 (2017-2028)
  • 欧州の経口粘膜薬物 市場規模：国別
    • 欧州の経口粘膜薬物の販売：国別 (2017-2028)
    • 欧州の経口粘膜薬物の収益：国別 (2017-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 アジア太平洋

  • アジア太平洋の経口粘膜薬物 市場規模：タイプ別
    • アジア太平洋の経口粘膜薬物の販売：タイプ別 (2017-2028)
    • アジア太平洋の経口粘膜薬物の収益：タイプ別 (2017-2028)
  • アジア太平洋の経口粘膜薬物 市場規模：アプリケーション別
    • アジア太平洋の経口粘膜薬物の販売：アプリケーション別 (2017-2028)
    • アジア太平洋の経口粘膜薬物の収益：アプリケーション別 (2017-2028)
  • アジア太平洋の経口粘膜薬物 市場規模：地域別
    • アジア太平洋の経口粘膜薬物の販売：地域別 (2017-2028)
    • アジア太平洋の経口粘膜薬物の収益：地域別 (2017-2028)
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • 台湾
    • インドネシア
    • タイ
    • マレーシア

第9章 ラテンアメリカ

  • ラテンアメリカの経口粘膜薬物 市場規模：タイプ別
    • ラテンアメリカの経口粘膜薬物の販売：タイプ別 (2017-2028)
    • ラテンアメリカの経口粘膜薬物の収益：タイプ別 (2017-2028)
  • ラテンアメリカの経口粘膜薬物 市場規模：アプリケーション別
    • ラテンアメリカの経口粘膜薬物の販売：アプリケーション別 (2017-2028)
    • ラテンアメリカの経口粘膜薬物の収益：アプリケーション別 (2017-2028)
  • ラテンアメリカの経口粘膜薬物 市場規模：国別
    • ラテンアメリカの経口粘膜薬物の販売：国別 (2017-2028)
    • ラテンアメリカの経口粘膜薬物の収益：国別 (2017-2028)
    • メキシコ
    • ブラジル
    • アルゼンチン

第10章 中東・アフリカ

  • 中東・アフリカの経口粘膜薬物 市場規模：タイプ別
    • 中東・アフリカの経口粘膜薬物の販売：タイプ別 (2017-2028)
    • 中東・アフリカの経口粘膜薬物の収益：タイプ別 (2017-2028)
  • 中東・アフリカの経口粘膜薬物 市場規模：アプリケーション別
    • 中東・アフリカの経口粘膜薬物の販売：アプリケーション別 (2017-2028)
    • 中東・アフリカの経口粘膜薬物の収益：アプリケーション別 (2017-2028)
  • 中東・アフリカの経口粘膜薬物 市場規模：国別
    • 中東・アフリカの経口粘膜薬物の販売：国別 (2017-2028)
    • 中東・アフリカの経口粘膜薬物の収益：国別 (2017-2028)
    • トルコ
    • サウジアラビア

第11章 企業プロファイル

  • LTS Lohmann Therapie-Systeme AG
  • Soligenix
  • ZIM Laboratories Limited
  • Access Pharmaceutical Inc.
  • C.L Pharm
  • Cure Pharmaceutical
  • Aquestive Therapeutics, Inc.
  • NAL Pharma
  • IntelGenx Corp.
  • Eisai Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Viatris
  • Bristol-Myers Squibb Company

第12章 業界チェーンと販売チャネルの分析

  • 経口粘膜薬物 業界チェーン分析
  • 経口粘膜薬物 主要原材料分析
    • 主要原材料分析
    • 原材料の主要サプライヤー
  • 経口粘膜薬物 生産形態とプロセス
  • 経口粘膜薬物 販売およびマーケティング
    • 経口粘膜薬物 販売チャネル
    • 経口粘膜薬物 卸業者
  • 経口粘膜薬物 顧客

第13章 市場の促進要因, 機会, 課題とリスク要因の分析

  • 経口粘膜薬物 業界動向
  • 経口粘膜薬物 市場の促進要因
  • 経口粘膜薬物 市場の課題
  • 経口粘膜薬物 市場の抑制要因

第14章 世界の経口粘膜薬物の主な市場調査結果

第15章 付録

図表
  • Table 1. Global Oral Transmucosal Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 2. Major Manufacturers of Tablets
  • Table 3. Major Manufacturers of Films
  • Table 4. Major Manufacturers of Liquid Spray
  • Table 5. Major Manufacturers of Gels
  • Table 6. Major Manufacturers of Others
  • Table 7. Global Oral Transmucosal Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 8. Global Oral Transmucosal Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
  • Table 9. Global Oral Transmucosal Drugs Sales by Region (2017-2022) & (K Units)
  • Table 10. Global Oral Transmucosal Drugs Sales Market Share by Region (2017-2022)
  • Table 11. Global Oral Transmucosal Drugs Sales by Region (2023-2028) & (K Units)
  • Table 12. Global Oral Transmucosal Drugs Sales Market Share by Region (2023-2028)
  • Table 13. Global Oral Transmucosal Drugs Revenue by Region (2017-2022) & (US$ Million)
  • Table 14. Global Oral Transmucosal Drugs Revenue Market Share by Region (2017-2022)
  • Table 15. Global Oral Transmucosal Drugs Revenue by Region (2023-2028) & (US$ Million)
  • Table 16. Global Oral Transmucosal Drugs Revenue Market Share by Region (2023-2028)
  • Table 17. Global Oral Transmucosal Drugs Sales by Manufacturers (2017-2022) & (K Units)
  • Table 18. Global Oral Transmucosal Drugs Sales Share by Manufacturers (2017-2022)
  • Table 19. Global Oral Transmucosal Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
  • Table 20. Global Oral Transmucosal Drugs Revenue Share by Manufacturers (2017-2022)
  • Table 21. Oral Transmucosal Drugs Price by Manufacturers (2017-2022) &(US$/Unit)
  • Table 22. Global Oral Transmucosal Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 23. Global Oral Transmucosal Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Transmucosal Drugs as of 2021)
  • Table 24. Oral Transmucosal Drugs Manufacturing Base Distribution and Headquarters
  • Table 25. Manufacturers Oral Transmucosal Drugs Product Offered
  • Table 26. Date of Manufacturers Enter into Oral Transmucosal Drugs Market
  • Table 27. Mergers & Acquisitions, Expansion Plans
  • Table 28. Global Oral Transmucosal Drugs Sales by Type (2017-2022) & (K Units)
  • Table 29. Global Oral Transmucosal Drugs Sales by Type (2023-2028) & (K Units)
  • Table 30. Global Oral Transmucosal Drugs Sales Share by Type (2017-2022)
  • Table 31. Global Oral Transmucosal Drugs Sales Share by Type (2023-2028)
  • Table 32. Global Oral Transmucosal Drugs Revenue by Type (2017-2022) & (US$ Million)
  • Table 33. Global Oral Transmucosal Drugs Revenue by Type (2023-2028) & (US$ Million)
  • Table 34. Global Oral Transmucosal Drugs Revenue Share by Type (2017-2022)
  • Table 35. Global Oral Transmucosal Drugs Revenue Share by Type (2023-2028)
  • Table 36. Oral Transmucosal Drugs Price by Type (2017-2022) & (US$/Unit)
  • Table 37. Global Oral Transmucosal Drugs Price Forecast by Type (2023-2028) & (US$/Unit)
  • Table 38. Global Oral Transmucosal Drugs Sales by Application (2017-2022) & (K Units)
  • Table 39. Global Oral Transmucosal Drugs Sales by Application (2023-2028) & (K Units)
  • Table 40. Global Oral Transmucosal Drugs Sales Share by Application (2017-2022)
  • Table 41. Global Oral Transmucosal Drugs Sales Share by Application (2023-2028)
  • Table 42. Global Oral Transmucosal Drugs Revenue by Application (2017-2022) & (US$ Million)
  • Table 43. Global Oral Transmucosal Drugs Revenue by Application (2023-2028) & (US$ Million)
  • Table 44. Global Oral Transmucosal Drugs Revenue Share by Application (2017-2022)
  • Table 45. Global Oral Transmucosal Drugs Revenue Share by Application (2023-2028)
  • Table 46. Oral Transmucosal Drugs Price by Application (2017-2022) & (US$/Unit)
  • Table 47. Global Oral Transmucosal Drugs Price Forecast by Application (2023-2028) & (US$/Unit)
  • Table 48. North America Oral Transmucosal Drugs Sales by Type (2017-2022) & (K Units)
  • Table 49. North America Oral Transmucosal Drugs Sales by Type (2023-2028) & (K Units)
  • Table 50. North America Oral Transmucosal Drugs Revenue by Type (2017-2022) & (US$ Million)
  • Table 51. North America Oral Transmucosal Drugs Revenue by Type (2023-2028) & (US$ Million)
  • Table 52. North America Oral Transmucosal Drugs Sales by Application (2017-2022) & (K Units)
  • Table 53. North America Oral Transmucosal Drugs Sales by Application (2023-2028) & (K Units)
  • Table 54. North America Oral Transmucosal Drugs Revenue by Application (2017-2022) & (US$ Million)
  • Table 55. North America Oral Transmucosal Drugs Revenue by Application (2023-2028) & (US$ Million)
  • Table 56. North America Oral Transmucosal Drugs Sales by Country (2017-2022) & (K Units)
  • Table 57. North America Oral Transmucosal Drugs Sales by Country (2023-2028) & (K Units)
  • Table 58. North America Oral Transmucosal Drugs Revenue by Country (2017-2022) & (US$ Million)
  • Table 59. North America Oral Transmucosal Drugs Revenue by Country (2023-2028) & (US$ Million)
  • Table 60. Europe Oral Transmucosal Drugs Sales by Type (2017-2022) & (K Units)
  • Table 61. Europe Oral Transmucosal Drugs Sales by Type (2023-2028) & (K Units)
  • Table 62. Europe Oral Transmucosal Drugs Revenue by Type (2017-2022) & (US$ Million)
  • Table 63. Europe Oral Transmucosal Drugs Revenue by Type (2023-2028) & (US$ Million)
  • Table 64. Europe Oral Transmucosal Drugs Sales by Application (2017-2022) & (K Units)
  • Table 65. Europe Oral Transmucosal Drugs Sales by Application (2023-2028) & (K Units)
  • Table 66. Europe Oral Transmucosal Drugs Revenue by Application (2017-2022) & (US$ Million)
  • Table 67. Europe Oral Transmucosal Drugs Revenue by Application (2023-2028) & (US$ Million)
  • Table 68. Europe Oral Transmucosal Drugs Sales by Country (2017-2022) & (K Units)
  • Table 69. Europe Oral Transmucosal Drugs Sales by Country (2023-2028) & (K Units)
  • Table 70. Europe Oral Transmucosal Drugs Revenue by Country (2017-2022) & (US$ Million)
  • Table 71. Europe Oral Transmucosal Drugs Revenue by Country (2023-2028) & (US$ Million)
  • Table 72. Asia Pacific Oral Transmucosal Drugs Sales by Type (2017-2022) & (K Units)
  • Table 73. Asia Pacific Oral Transmucosal Drugs Sales by Type (2023-2028) & (K Units)
  • Table 74. Asia Pacific Oral Transmucosal Drugs Revenue by Type (2017-2022) & (US$ Million)
  • Table 75. Asia Pacific Oral Transmucosal Drugs Revenue by Type (2023-2028) & (US$ Million)
  • Table 76. Asia Pacific Oral Transmucosal Drugs Sales by Application (2017-2022) & (K Units)
  • Table 77. Asia Pacific Oral Transmucosal Drugs Sales by Application (2023-2028) & (K Units)
  • Table 78. Asia Pacific Oral Transmucosal Drugs Revenue by Application (2017-2022) & (US$ Million)
  • Table 79. Asia Pacific Oral Transmucosal Drugs Revenue by Application (2023-2028) & (US$ Million)
  • Table 80. Asia Pacific Oral Transmucosal Drugs Sales by Region (2017-2022) & (K Units)
  • Table 81. Asia Pacific Oral Transmucosal Drugs Sales by Region (2023-2028) & (K Units)
  • Table 82. Asia Pacific Oral Transmucosal Drugs Revenue by Region (2017-2022) & (US$ Million)
  • Table 83. Asia Pacific Oral Transmucosal Drugs Revenue by Region (2023-2028) & (US$ Million)
  • Table 84. Latin America Oral Transmucosal Drugs Sales by Type (2017-2022) & (K Units)
  • Table 85. Latin America Oral Transmucosal Drugs Sales by Type (2023-2028) & (K Units)
  • Table 86. Latin America Oral Transmucosal Drugs Revenue by Type (2017-2022) & (US$ Million)
  • Table 87. Latin America Oral Transmucosal Drugs Revenue by Type (2023-2028) & (US$ Million)
  • Table 88. Latin America Oral Transmucosal Drugs Sales by Application (2017-2022) & (K Units)
  • Table 89. Latin America Oral Transmucosal Drugs Sales by Application (2023-2028) & (K Units)
  • Table 90. Latin America Oral Transmucosal Drugs Revenue by Application (2017-2022) & (US$ Million)
  • Table 91. Latin America Oral Transmucosal Drugs Revenue by Application (2023-2028) & (US$ Million)
  • Table 92. Latin America Oral Transmucosal Drugs Sales by Country (2017-2022) & (K Units)
  • Table 93. Latin America Oral Transmucosal Drugs Sales by Country (2023-2028) & (K Units)
  • Table 94. Latin America Oral Transmucosal Drugs Revenue by Country (2017-2022) & (US$ Million)
  • Table 95. Latin America Oral Transmucosal Drugs Revenue by Country (2023-2028) & (US$ Million)
  • Table 96. Middle East and Africa Oral Transmucosal Drugs Sales by Type (2017-2022) & (K Units)
  • Table 97. Middle East and Africa Oral Transmucosal Drugs Sales by Type (2023-2028) & (K Units)
  • Table 98. Middle East and Africa Oral Transmucosal Drugs Revenue by Type (2017-2022) & (US$ Million)
  • Table 99. Middle East and Africa Oral Transmucosal Drugs Revenue by Type (2023-2028) & (US$ Million)
  • Table 100. Middle East and Africa Oral Transmucosal Drugs Sales by Application (2017-2022) & (K Units)
  • Table 101. Middle East and Africa Oral Transmucosal Drugs Sales by Application (2023-2028) & (K Units)
  • Table 102. Middle East and Africa Oral Transmucosal Drugs Revenue by Application (2017-2022) & (US$ Million)
  • Table 103. Middle East and Africa Oral Transmucosal Drugs Revenue by Application (2023-2028) & (US$ Million)
  • Table 104. Middle East and Africa Oral Transmucosal Drugs Sales by Country (2017-2022) & (K Units)
  • Table 105. Middle East and Africa Oral Transmucosal Drugs Sales by Country (2023-2028) & (K Units)
  • Table 106. Middle East and Africa Oral Transmucosal Drugs Revenue by Country (2017-2022) & (US$ Million)
  • Table 107. Middle East and Africa Oral Transmucosal Drugs Revenue by Country (2023-2028) & (US$ Million)
  • Table 108. LTS Lohmann Therapie-Systeme AG Corporation Information
  • Table 109. LTS Lohmann Therapie-Systeme AG Description and Major Businesses
  • Table 110. LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 111. LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 112. LTS Lohmann Therapie-Systeme AG Recent Developments
  • Table 113. Soligenix Corporation Information
  • Table 114. Soligenix Description and Major Businesses
  • Table 115. Soligenix Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 116. Soligenix Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 117. Soligenix Recent Developments
  • Table 118. ZIM Laboratories Limited Corporation Information
  • Table 119. ZIM Laboratories Limited Description and Major Businesses
  • Table 120. ZIM Laboratories Limited Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 121. ZIM Laboratories Limited Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 122. ZIM Laboratories Limited Recent Developments
  • Table 123. Access Pharmaceutical Inc. Corporation Information
  • Table 124. Access Pharmaceutical Inc. Description and Major Businesses
  • Table 125. Access Pharmaceutical Inc. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 126. Access Pharmaceutical Inc. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 127. Access Pharmaceutical Inc. Recent Developments
  • Table 128. C.L Pharm Corporation Information
  • Table 129. C.L Pharm Description and Major Businesses
  • Table 130. C.L Pharm Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 131. C.L Pharm Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 132. C.L Pharm Recent Developments
  • Table 133. Cure Pharmaceutical Corporation Information
  • Table 134. Cure Pharmaceutical Description and Major Businesses
  • Table 135. Cure Pharmaceutical Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 136. Cure Pharmaceutical Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 137. Cure Pharmaceutical Recent Developments
  • Table 138. Aquestive Therapeutics, Inc. Corporation Information
  • Table 139. Aquestive Therapeutics, Inc. Description and Major Businesses
  • Table 140. Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 141. Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 142. Aquestive Therapeutics, Inc. Recent Developments
  • Table 143. NAL Pharma Corporation Information
  • Table 144. NAL Pharma Description and Major Businesses
  • Table 145. NAL Pharma Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 146. NAL Pharma Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 147. NAL Pharma Recent Developments
  • Table 148. IntelGenx Corp. Corporation Information
  • Table 149. IntelGenx Corp. Description and Major Businesses
  • Table 150. IntelGenx Corp. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 151. IntelGenx Corp. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 152. IntelGenx Corp. Recent Developments
  • Table 153. Eisai Co., Ltd. Corporation Information
  • Table 154. Eisai Co., Ltd. Description and Major Businesses
  • Table 155. Eisai Co., Ltd. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 156. Eisai Co., Ltd. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 157. Eisai Co., Ltd. Recent Developments
  • Table 158. Otsuka Pharmaceutical Co., Ltd. Corporation Information
  • Table 159. Otsuka Pharmaceutical Co., Ltd. Description and Major Businesses
  • Table 160. Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 161. Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 162. Otsuka Pharmaceutical Co., Ltd. Recent Developments
  • Table 163. Teva Pharmaceutical Industries Ltd. Corporation Information
  • Table 164. Teva Pharmaceutical Industries Ltd. Description and Major Businesses
  • Table 165. Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 166. Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 167. Teva Pharmaceutical Industries Ltd. Recent Developments
  • Table 168. GlaxoSmithKline plc Corporation Information
  • Table 169. GlaxoSmithKline plc Description and Major Businesses
  • Table 170. GlaxoSmithKline plc Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 171. GlaxoSmithKline plc Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 172. GlaxoSmithKline plc Recent Developments
  • Table 173. Viatris Corporation Information
  • Table 174. Viatris Description and Major Businesses
  • Table 175. Viatris Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 176. Viatris Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 177. Viatris Recent Developments
  • Table 178. Bristol-Myers Squibb Company Corporation Information
  • Table 179. Bristol-Myers Squibb Company Description and Major Businesses
  • Table 180. Bristol-Myers Squibb Company Oral Transmucosal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 181. Bristol-Myers Squibb Company Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 182. Bristol-Myers Squibb Company Recent Developments
  • Table 183. Key Raw Materials Lists
  • Table 184. Raw Materials Key Suppliers Lists
  • Table 185. Oral Transmucosal Drugs Distributors List
  • Table 186. Oral Transmucosal Drugs Customers List
  • Table 187. Oral Transmucosal Drugs Market Trends
  • Table 188. Oral Transmucosal Drugs Market Drivers
  • Table 189. Oral Transmucosal Drugs Market Challenges
  • Table 190. Oral Transmucosal Drugs Market Restraints
  • Table 191. Research Programs/Design for This Report
  • Table 192. Key Data Information from Secondary Sources
  • Table 193. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Oral Transmucosal Drugs Product Picture
  • Figure 3. Global Oral Transmucosal Drugs Market Share by Type in 2021 & 2028
  • Figure 3. Tablets Product Picture
  • Figure 4. Films Product Picture
  • Figure 5. Liquid Spray Product Picture
  • Figure 6. Gels Product Picture
  • Figure 7. Others Product Picture
  • Figure 8. Global Oral Transmucosal Drugs Market Share by Application in 2021 & 2028
  • Figure 9. Cardiovascular Disorders
  • Figure 10. Acute Pain Managements
  • Figure 11. Diabetes
  • Figure 12. Others
  • Figure 13. Oral Transmucosal Drugs Report Years Considered
  • Figure 14. Global Oral Transmucosal Drugs Sales 2017-2028 (K Units)
  • Figure 15. Global Oral Transmucosal Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 16. Global Oral Transmucosal Drugs Revenue 2017-2028 (US$ Million)
  • Figure 17. Global Oral Transmucosal Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
  • Figure 18. Global Oral Transmucosal Drugs Sales Market Share by Region (2017-2022)
  • Figure 19. Global Oral Transmucosal Drugs Sales Market Share by Region (2023-2028)
  • Figure 20. North America Oral Transmucosal Drugs Sales YoY (2017-2028) & (K Units)
  • Figure 21. North America Oral Transmucosal Drugs Revenue YoY (2017-2028) & (US$ Million)
  • Figure 22. Europe Oral Transmucosal Drugs Sales YoY (2017-2028) & (K Units)
  • Figure 23. Europe Oral Transmucosal Drugs Revenue YoY (2017-2028) & (US$ Million)
  • Figure 24. Asia-Pacific Oral Transmucosal Drugs Sales YoY (2017-2028) & (K Units)
  • Figure 25. Asia-Pacific Oral Transmucosal Drugs Revenue YoY (2017-2028) & (US$ Million)
  • Figure 26. Latin America Oral Transmucosal Drugs Sales YoY (2017-2028) & (K Units)
  • Figure 27. Latin America Oral Transmucosal Drugs Revenue YoY (2017-2028) & (US$ Million)
  • Figure 28. Middle East & Africa Oral Transmucosal Drugs Sales YoY (2017-2028) & (K Units)
  • Figure 29. Middle East & Africa Oral Transmucosal Drugs Revenue YoY (2017-2028) & (US$ Million)
  • Figure 30. The Oral Transmucosal Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
  • Figure 31. The Top 5 and 10 Largest Manufacturers of Oral Transmucosal Drugs in the World: Market Share by Oral Transmucosal Drugs Revenue in 2021
  • Figure 32. Global Oral Transmucosal Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
  • Figure 33. Global Oral Transmucosal Drugs Sales Market Share by Type (2017-2028)
  • Figure 34. Global Oral Transmucosal Drugs Revenue Market Share by Type (2017-2028)
  • Figure 35. Global Oral Transmucosal Drugs Sales Market Share by Application (2017-2028)
  • Figure 36. Global Oral Transmucosal Drugs Revenue Market Share by Application (2017-2028)
  • Figure 37. North America Oral Transmucosal Drugs Sales Market Share by Type (2017-2028)
  • Figure 38. North America Oral Transmucosal Drugs Revenue Market Share by Type (2017-2028)
  • Figure 39. North America Oral Transmucosal Drugs Sales Market Share by Application (2017-2028)
  • Figure 40. North America Oral Transmucosal Drugs Revenue Market Share by Application (2017-2028)
  • Figure 41. North America Oral Transmucosal Drugs Sales Share by Country (2017-2028)
  • Figure 42. North America Oral Transmucosal Drugs Revenue Share by Country (2017-2028)
  • Figure 43. United States Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 44. Canada Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 45. Europe Oral Transmucosal Drugs Sales Market Share by Type (2017-2028)
  • Figure 46. Europe Oral Transmucosal Drugs Revenue Market Share by Type (2017-2028)
  • Figure 47. Europe Oral Transmucosal Drugs Sales Market Share by Application (2017-2028)
  • Figure 48. Europe Oral Transmucosal Drugs Revenue Market Share by Application (2017-2028)
  • Figure 49. Europe Oral Transmucosal Drugs Sales Share by Country (2017-2028)
  • Figure 50. Europe Oral Transmucosal Drugs Revenue Share by Country (2017-2028)
  • Figure 51. Germany Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 52. France Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 53. U.K. Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 54. Italy Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 55. Russia Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 56. Asia Pacific Oral Transmucosal Drugs Sales Market Share by Type (2017-2028)
  • Figure 57. Asia Pacific Oral Transmucosal Drugs Revenue Market Share by Type (2017-2028)
  • Figure 58. Asia Pacific Oral Transmucosal Drugs Sales Market Share by Application (2017-2028)
  • Figure 59. Asia Pacific Oral Transmucosal Drugs Revenue Market Share by Application (2017-2028)
  • Figure 60. Asia Pacific Oral Transmucosal Drugs Sales Share by Region (2017-2028)
  • Figure 61. Asia Pacific Oral Transmucosal Drugs Revenue Share by Region (2017-2028)
  • Figure 62. China Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 63. Japan Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 64. South Korea Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 65. India Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 66. Australia Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 67. China Taiwan Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 68. Indonesia Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 69. Thailand Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 70. Malaysia Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 71. Latin America Oral Transmucosal Drugs Sales Market Share by Type (2017-2028)
  • Figure 72. Latin America Oral Transmucosal Drugs Revenue Market Share by Type (2017-2028)
  • Figure 73. Latin America Oral Transmucosal Drugs Sales Market Share by Application (2017-2028)
  • Figure 74. Latin America Oral Transmucosal Drugs Revenue Market Share by Application (2017-2028)
  • Figure 75. Latin America Oral Transmucosal Drugs Sales Share by Country (2017-2028)
  • Figure 76. Latin America Oral Transmucosal Drugs Revenue Share by Country (2017-2028)
  • Figure 77. Mexico Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 78. Brazil Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 79. Argentina Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 80. Middle East and Africa Oral Transmucosal Drugs Sales Market Share by Type (2017-2028)
  • Figure 81. Middle East and Africa Oral Transmucosal Drugs Revenue Market Share by Type (2017-2028)
  • Figure 82. Middle East and Africa Oral Transmucosal Drugs Sales Market Share by Application (2017-2028)
  • Figure 83. Middle East and Africa Oral Transmucosal Drugs Revenue Market Share by Application (2017-2028)
  • Figure 84. Middle East and Africa Oral Transmucosal Drugs Sales Share by Country (2017-2028)
  • Figure 85. Middle East and Africa Oral Transmucosal Drugs Revenue Share by Country (2017-2028)
  • Figure 86. Turkey Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 87. Saudi Arabia Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 88. UAE Oral Transmucosal Drugs Revenue (2017-2028) & (US$ Million)
  • Figure 89. Oral Transmucosal Drugs Value Chain
  • Figure 90. Oral Transmucosal Drugs Production Process
  • Figure 91. Channels of Distribution
  • Figure 92. Distributors Profiles
  • Figure 93. Bottom-up and Top-down Approaches for This Report
  • Figure 94. Data Triangulation
  • Figure 95. Key Executives Interviewed
目次

This research report focuses on the Oral Transmucosal Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Oral Transmucosal Drugs Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Oral Transmucosal Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Tablets
    • 1.2.3 Films
    • 1.2.4 Liquid Spray
    • 1.2.5 Gels
    • 1.2.6 Others
  • 1.3 Market by Application
    • 1.3.1 Global Oral Transmucosal Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Cardiovascular Disorders
    • 1.3.3 Acute Pain Managements
    • 1.3.4 Diabetes
    • 1.3.5 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Oral Transmucosal Drugs Sales Estimates and Forecasts 2017-2028
  • 2.2 Global Oral Transmucosal Drugs Revenue Estimates and Forecasts 2017-2028
  • 2.3 Global Oral Transmucosal Drugs Revenue by Region: 2017 VS 2021 VS 2028
  • 2.4 Global Oral Transmucosal Drugs Sales by Region
    • 2.4.1 Global Oral Transmucosal Drugs Sales by Region (2017-2022)
    • 2.4.2 Global Sales Oral Transmucosal Drugs by Region (2023-2028)
  • 2.5 Global Oral Transmucosal Drugs Revenue by Region
    • 2.5.1 Global Oral Transmucosal Drugs Revenue by Region (2017-2022)
    • 2.5.2 Global Oral Transmucosal Drugs Revenue by Region (2023-2028)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Oral Transmucosal Drugs Sales by Manufacturers
    • 3.1.1 Global Top Oral Transmucosal Drugs Manufacturers by Sales (2017-2022)
    • 3.1.2 Global Oral Transmucosal Drugs Sales Market Share by Manufacturers (2017-2022)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oral Transmucosal Drugs in 2021
  • 3.2 Global Oral Transmucosal Drugs Revenue by Manufacturers
    • 3.2.1 Global Oral Transmucosal Drugs Revenue by Manufacturers (2017-2022)
    • 3.2.2 Global Oral Transmucosal Drugs Revenue Market Share by Manufacturers (2017-2022)
    • 3.2.3 Global Top 10 and Top 5 Companies by Oral Transmucosal Drugs Revenue in 2021
  • 3.3 Global Oral Transmucosal Drugs Sales Price by Manufacturers (2017-2022)
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Oral Transmucosal Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Oral Transmucosal Drugs Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Oral Transmucosal Drugs Sales by Type
    • 4.1.1 Global Oral Transmucosal Drugs Historical Sales by Type (2017-2022)
    • 4.1.2 Global Oral Transmucosal Drugs Forecasted Sales by Type (2023-2028)
    • 4.1.3 Global Oral Transmucosal Drugs Sales Market Share by Type (2017-2028)
  • 4.2 Global Oral Transmucosal Drugs Revenue by Type
    • 4.2.1 Global Oral Transmucosal Drugs Historical Revenue by Type (2017-2022)
    • 4.2.2 Global Oral Transmucosal Drugs Forecasted Revenue by Type (2023-2028)
    • 4.2.3 Global Oral Transmucosal Drugs Revenue Market Share by Type (2017-2028)
  • 4.3 Global Oral Transmucosal Drugs Price by Type
    • 4.3.1 Global Oral Transmucosal Drugs Price by Type (2017-2022)
    • 4.3.2 Global Oral Transmucosal Drugs Price Forecast by Type (2023-2028)

5 Market Size by Application

  • 5.1 Global Oral Transmucosal Drugs Sales by Application
    • 5.1.1 Global Oral Transmucosal Drugs Historical Sales by Application (2017-2022)
    • 5.1.2 Global Oral Transmucosal Drugs Forecasted Sales by Application (2023-2028)
    • 5.1.3 Global Oral Transmucosal Drugs Sales Market Share by Application (2017-2028)
  • 5.2 Global Oral Transmucosal Drugs Revenue by Application
    • 5.2.1 Global Oral Transmucosal Drugs Historical Revenue by Application (2017-2022)
    • 5.2.2 Global Oral Transmucosal Drugs Forecasted Revenue by Application (2023-2028)
    • 5.2.3 Global Oral Transmucosal Drugs Revenue Market Share by Application (2017-2028)
  • 5.3 Global Oral Transmucosal Drugs Price by Application
    • 5.3.1 Global Oral Transmucosal Drugs Price by Application (2017-2022)
    • 5.3.2 Global Oral Transmucosal Drugs Price Forecast by Application (2023-2028)

6 North America

  • 6.1 North America Oral Transmucosal Drugs Market Size by Type
    • 6.1.1 North America Oral Transmucosal Drugs Sales by Type (2017-2028)
    • 6.1.2 North America Oral Transmucosal Drugs Revenue by Type (2017-2028)
  • 6.2 North America Oral Transmucosal Drugs Market Size by Application
    • 6.2.1 North America Oral Transmucosal Drugs Sales by Application (2017-2028)
    • 6.2.2 North America Oral Transmucosal Drugs Revenue by Application (2017-2028)
  • 6.3 North America Oral Transmucosal Drugs Market Size by Country
    • 6.3.1 North America Oral Transmucosal Drugs Sales by Country (2017-2028)
    • 6.3.2 North America Oral Transmucosal Drugs Revenue by Country (2017-2028)
    • 6.3.3 United States
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Oral Transmucosal Drugs Market Size by Type
    • 7.1.1 Europe Oral Transmucosal Drugs Sales by Type (2017-2028)
    • 7.1.2 Europe Oral Transmucosal Drugs Revenue by Type (2017-2028)
  • 7.2 Europe Oral Transmucosal Drugs Market Size by Application
    • 7.2.1 Europe Oral Transmucosal Drugs Sales by Application (2017-2028)
    • 7.2.2 Europe Oral Transmucosal Drugs Revenue by Application (2017-2028)
  • 7.3 Europe Oral Transmucosal Drugs Market Size by Country
    • 7.3.1 Europe Oral Transmucosal Drugs Sales by Country (2017-2028)
    • 7.3.2 Europe Oral Transmucosal Drugs Revenue by Country (2017-2028)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Oral Transmucosal Drugs Market Size by Type
    • 8.1.1 Asia Pacific Oral Transmucosal Drugs Sales by Type (2017-2028)
    • 8.1.2 Asia Pacific Oral Transmucosal Drugs Revenue by Type (2017-2028)
  • 8.2 Asia Pacific Oral Transmucosal Drugs Market Size by Application
    • 8.2.1 Asia Pacific Oral Transmucosal Drugs Sales by Application (2017-2028)
    • 8.2.2 Asia Pacific Oral Transmucosal Drugs Revenue by Application (2017-2028)
  • 8.3 Asia Pacific Oral Transmucosal Drugs Market Size by Region
    • 8.3.1 Asia Pacific Oral Transmucosal Drugs Sales by Region (2017-2028)
    • 8.3.2 Asia Pacific Oral Transmucosal Drugs Revenue by Region (2017-2028)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 China Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia

9 Latin America

  • 9.1 Latin America Oral Transmucosal Drugs Market Size by Type
    • 9.1.1 Latin America Oral Transmucosal Drugs Sales by Type (2017-2028)
    • 9.1.2 Latin America Oral Transmucosal Drugs Revenue by Type (2017-2028)
  • 9.2 Latin America Oral Transmucosal Drugs Market Size by Application
    • 9.2.1 Latin America Oral Transmucosal Drugs Sales by Application (2017-2028)
    • 9.2.2 Latin America Oral Transmucosal Drugs Revenue by Application (2017-2028)
  • 9.3 Latin America Oral Transmucosal Drugs Market Size by Country
    • 9.3.1 Latin America Oral Transmucosal Drugs Sales by Country (2017-2028)
    • 9.3.2 Latin America Oral Transmucosal Drugs Revenue by Country (2017-2028)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

10 Middle East and Africa

  • 10.1 Middle East and Africa Oral Transmucosal Drugs Market Size by Type
    • 10.1.1 Middle East and Africa Oral Transmucosal Drugs Sales by Type (2017-2028)
    • 10.1.2 Middle East and Africa Oral Transmucosal Drugs Revenue by Type (2017-2028)
  • 10.2 Middle East and Africa Oral Transmucosal Drugs Market Size by Application
    • 10.2.1 Middle East and Africa Oral Transmucosal Drugs Sales by Application (2017-2028)
    • 10.2.2 Middle East and Africa Oral Transmucosal Drugs Revenue by Application (2017-2028)
  • 10.3 Middle East and Africa Oral Transmucosal Drugs Market Size by Country
    • 10.3.1 Middle East and Africa Oral Transmucosal Drugs Sales by Country (2017-2028)
    • 10.3.2 Middle East and Africa Oral Transmucosal Drugs Revenue by Country (2017-2028)
    • 10.3.3 Turkey
    • 10.3.4 Saudi Arabia

11 Company Profiles

  • 11.1 LTS Lohmann Therapie-Systeme AG
    • 11.1.1 LTS Lohmann Therapie-Systeme AG Corporation Information
    • 11.1.2 LTS Lohmann Therapie-Systeme AG Overview
    • 11.1.3 LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.1.4 LTS Lohmann Therapie-Systeme AG Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 LTS Lohmann Therapie-Systeme AG Recent Developments
  • 11.2 Soligenix
    • 11.2.1 Soligenix Corporation Information
    • 11.2.2 Soligenix Overview
    • 11.2.3 Soligenix Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.2.4 Soligenix Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Soligenix Recent Developments
  • 11.3 ZIM Laboratories Limited
    • 11.3.1 ZIM Laboratories Limited Corporation Information
    • 11.3.2 ZIM Laboratories Limited Overview
    • 11.3.3 ZIM Laboratories Limited Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.3.4 ZIM Laboratories Limited Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 ZIM Laboratories Limited Recent Developments
  • 11.4 Access Pharmaceutical Inc.
    • 11.4.1 Access Pharmaceutical Inc. Corporation Information
    • 11.4.2 Access Pharmaceutical Inc. Overview
    • 11.4.3 Access Pharmaceutical Inc. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.4.4 Access Pharmaceutical Inc. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 Access Pharmaceutical Inc. Recent Developments
  • 11.5 C.L Pharm
    • 11.5.1 C.L Pharm Corporation Information
    • 11.5.2 C.L Pharm Overview
    • 11.5.3 C.L Pharm Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.5.4 C.L Pharm Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 C.L Pharm Recent Developments
  • 11.6 Cure Pharmaceutical
    • 11.6.1 Cure Pharmaceutical Corporation Information
    • 11.6.2 Cure Pharmaceutical Overview
    • 11.6.3 Cure Pharmaceutical Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.6.4 Cure Pharmaceutical Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Cure Pharmaceutical Recent Developments
  • 11.7 Aquestive Therapeutics, Inc.
    • 11.7.1 Aquestive Therapeutics, Inc. Corporation Information
    • 11.7.2 Aquestive Therapeutics, Inc. Overview
    • 11.7.3 Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.7.4 Aquestive Therapeutics, Inc. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 Aquestive Therapeutics, Inc. Recent Developments
  • 11.8 NAL Pharma
    • 11.8.1 NAL Pharma Corporation Information
    • 11.8.2 NAL Pharma Overview
    • 11.8.3 NAL Pharma Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.8.4 NAL Pharma Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 NAL Pharma Recent Developments
  • 11.9 IntelGenx Corp.
    • 11.9.1 IntelGenx Corp. Corporation Information
    • 11.9.2 IntelGenx Corp. Overview
    • 11.9.3 IntelGenx Corp. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.9.4 IntelGenx Corp. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.9.5 IntelGenx Corp. Recent Developments
  • 11.10 Eisai Co., Ltd.
    • 11.10.1 Eisai Co., Ltd. Corporation Information
    • 11.10.2 Eisai Co., Ltd. Overview
    • 11.10.3 Eisai Co., Ltd. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.10.4 Eisai Co., Ltd. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.10.5 Eisai Co., Ltd. Recent Developments
  • 11.11 Otsuka Pharmaceutical Co., Ltd.
    • 11.11.1 Otsuka Pharmaceutical Co., Ltd. Corporation Information
    • 11.11.2 Otsuka Pharmaceutical Co., Ltd. Overview
    • 11.11.3 Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.11.4 Otsuka Pharmaceutical Co., Ltd. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.11.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
  • 11.12 Teva Pharmaceutical Industries Ltd.
    • 11.12.1 Teva Pharmaceutical Industries Ltd. Corporation Information
    • 11.12.2 Teva Pharmaceutical Industries Ltd. Overview
    • 11.12.3 Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.12.4 Teva Pharmaceutical Industries Ltd. Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  • 11.13 GlaxoSmithKline plc
    • 11.13.1 GlaxoSmithKline plc Corporation Information
    • 11.13.2 GlaxoSmithKline plc Overview
    • 11.13.3 GlaxoSmithKline plc Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.13.4 GlaxoSmithKline plc Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.13.5 GlaxoSmithKline plc Recent Developments
  • 11.14 Viatris
    • 11.14.1 Viatris Corporation Information
    • 11.14.2 Viatris Overview
    • 11.14.3 Viatris Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.14.4 Viatris Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.14.5 Viatris Recent Developments
  • 11.15 Bristol-Myers Squibb Company
    • 11.15.1 Bristol-Myers Squibb Company Corporation Information
    • 11.15.2 Bristol-Myers Squibb Company Overview
    • 11.15.3 Bristol-Myers Squibb Company Oral Transmucosal Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.15.4 Bristol-Myers Squibb Company Oral Transmucosal Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.15.5 Bristol-Myers Squibb Company Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Oral Transmucosal Drugs Industry Chain Analysis
  • 12.2 Oral Transmucosal Drugs Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Oral Transmucosal Drugs Production Mode & Process
  • 12.4 Oral Transmucosal Drugs Sales and Marketing
    • 12.4.1 Oral Transmucosal Drugs Sales Channels
    • 12.4.2 Oral Transmucosal Drugs Distributors
  • 12.5 Oral Transmucosal Drugs Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Oral Transmucosal Drugs Industry Trends
  • 13.2 Oral Transmucosal Drugs Market Drivers
  • 13.3 Oral Transmucosal Drugs Market Challenges
  • 13.4 Oral Transmucosal Drugs Market Restraints

14 Key Findings in The Global Oral Transmucosal Drugs Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer